Juan Wu^1,2, Yue Wang³, Honglin Yan¹, Juanjuan Li², Chuntao Quan^4,*, Jingping Yuan^1,*, Shengrong Sun^2,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.081653 - 16 July 2026

Abstract Objectives: Despite the success of CDK4/6 inhibitors (CDK4/6i) in treating HR+/HER2- breast cancer (BC), some patients experience treatment failure due to CDK4/6i resistance. This study aimed to investigate whether targeting Aurora A kinase enhances CDK4/6 inhibitor sensitivity. Methods: An Abemaciclib-resistant cell line (MCF7AR) was developed by treating MCF7 cells with gradually increasing concentrations of Abemaciclib. We evaluated the relative protein levels of p-RB, p-Aurora A, Aurora A, and USP22 in cell cultures, animal tissues, and clinical samples. The effect of Aurora A inhibition on reversing CDK4/6i resistance was assessed using cell viability assays and tumor… More >

Liang Li^1,#, Hong Deng^2,#, Zhiyong Li², Yu Li², Lingrui Liu², Lan Xie^2,*, Yue Chen^3,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.081109 - 16 July 2026

Abstract Objectives: Oral squamous cell carcinoma (OSCC) is a common and deadly cancer affecting the oral cavity. This study aims to explore the regulatory role and molecular mechanism of miR-548ae-3p in OSCC proliferation, invasion, and lipid metabolism, as well as the therapeutic potential of isoliquiritigenin (ISL) targeting OSCC lipid metabolism. Methods: Expression levels of miR-548ae-3p were measured in OSCC cell lines and normal oral keratinocytes using real-time quantitative polymerase chain reaction. Functional assays, such as cell counting Kit-8 proliferation and Transwell invasion assays, evaluated the effects of miR-548ae-3p overexpression in CAL-27 and SCC-25 cells. Bioinformatic prediction and… More >

Shidi Wen^1,2,#, Lu Wang^1,2,#, Ying Jiang³, Zhiyang Zhang^4,*, Yuejuan Cheng^4,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.080462 - 16 July 2026

Abstract Background: Hidradenocarcinoma is a rare and highly aggressive malignancy with limited therapeutic options. This report describes the clinical course and treatment response of a patient with recurrent metastatic hidradenocarcinoma treated with sequential immunochemotherapy combined with anti-angiogenic therapy, with the aim of providing further insight into potential treatment strategies for this rare malignancy. Case Description: A 60-year-old male initially presented in 2020 with scrotal erythema and was diagnosed with hidradenocarcinoma after surgery. Despite surgical treatment, he developed recurrent disease with diffuse metastases. First-line chemoimmunotherapy (sintilimab, cisplatin, 5-fluorouracil; six cycles) achieved a progression-free survival (PFS) of 6 months. Following… More >

Haijun Sun^1,#, Wenyue Yan^2,#, Zhanyu Li^3,#, Qintian Li⁴, Qilong Du⁴, Li Xu⁵, Wanwei Cao³, Junrong Yang⁶, Xilan Yang², Jun Chen^7,*, Yuan Mao^8,*, Wen Huang^4,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.080413 - 16 July 2026

Abstract Background: The melanoma-associated antigen-A1 (MAGE-A1) demonstrates tumor-restricted expression patterns in diverse malignancies, positioning it as an attractive therapeutic target. This investigation aimed to engineer and validate a novel antibody-drug conjugate with oxaliplatin targeting MAGE-Al (MIg-OXA), a novel antibody-drug conjugate targeting MAGE-A1, while assessing its therapeutic potential against MAGE-A1-expressing lung adenocarcinoma through both cellular and animal models. Methods: We generated a MAGE-A1-specific immunoglobulin G (IgG) antibody (MIgG) and subsequently conjugated it with oxaliplatin (OXA) to produce MIgG-OXA. The conjugate’s binding specificity and cellular uptake were verified through cell-based enzyme-linked immunosorbent assay (ELISA), flow cytometric analysis, and immunofluorescence… More >

Cristian Cojocaru, Marcel Costuleanu^*, Ovidiu Rusalim Petriș, Ruxandra Cojocaru, Decebal Vasîncu, Elena Cojocaru

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.080024 - 16 July 2026

Abstract Lung cancer in individuals who have never smoked (LCINS) represents a clinically and biologically distinct subset of non–small cell lung cancer, driven predominantly by oncogenic alterations rather than tobacco-related mutagenesis. This review aims to summarize current and emerging targeted and immune-based therapeutic strategies in LCINS individuals. These patients present a molecular profile that differs substantially from tobacco-associated disease and has direct consequences for treatment selection. Evidence published over the past five years has clarified how these molecular features shape treatment response and resistance in this setting. Particular attention is given to tumors with alterations in… More >

Shijia Lu^1,#, Yanmin Wang^1,#, Han Zhang¹, Mengjia Yan¹, Mengdan Sang², Jinle Wang¹, Huaying Du³, Jinwen Sima³, Yiran Zhen², Xue Yang², Yutong Zhang¹, Hongwei Zhou^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079988 - 16 July 2026

Abstract Proliferating Cell Nuclear Antigen (PCNA) is a core protein in DNA replication and repair. Its functional dysregulation drives tumorigenesis and therapeutic resistance, making it a critical anticancer target. However, the fundamental conflict between PCNA’s indispensable “guardian” function in normal cells and its hijacked “accomplice” role in cancer cells constitutes the central challenge for targeted intervention: how to eradicate tumors while avoiding severe toxicity to normal tissues. This review aims to systematically review the latest advances and translational dilemmas in the field of PCNA-targeted therapy. It outlines various intervention strategies, including small-molecule inhibitors, proteolysis-targeting chimeras, post-translational More > Graphic Abstract

Xin Qian, Xian Deng, Rongjia Zhang, Xu Li, Dehui Qiao, Xiaodong Chen, Hui Yang^*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079674 - 16 July 2026

Abstract Background: Poorly differentiated thyroid carcinoma (PDTC) is a rare, aggressive malignancy. Cardiac metastasis from PDTC is exceedingly uncommon. We report early cardiac metastasis occurring shortly after radical thyroidectomy to highlight atypical distant spread and management challenges. Case Description: A 62-year-old woman presented four months after thyroidectomy with progressive exertional dyspnoea, fatigue, productive cough, facial oedema, lip cyanosis, and dizziness. Postoperative pathology showed poorly differentiated thyroid carcinoma of the right lobe and isthmus (pT2N1bM0) with capsular and recurrent laryngeal nerve invasion. Transthoracic echocardiography revealed a right atrial mass that enlarged to 5.3 × 4.0 cm and extended toward… More >

Yaqi Xu¹, Jia Zhao², Xiaowen Mao^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079562 - 16 July 2026

Abstract Extracellular vesicles (EVs) are actively secreted, membrane-enclosed nanoparticles that serve as pivotal mediators of intercellular communication. They function as key mediators of intercellular communication by transporting diverse biomolecules, including proteins, nucleic acids, and metabolites. Within the tumor microenvironment, EVs drive complex cellular crosstalk and critically regulate tumor progression by remodeling the extracellular matrix, conferring drug resistance, and reprogramming immune responses. Given their natural biocompatibility, tissue tropism, and ability to cross biological barriers, EVs have emerged as promising platforms for immunotherapy, tumor vaccines and targeted drug delivery system. Moreover, the rapid expansion of EV-based clinical trials… More > Graphic Abstract

Yiming Ma^1,2,#, Zhihan Zhang^1,2,#, Hongli Pan³, Hailin Jiang^1,2, Lili Guo^4,*, Fengjie Guo^1,2,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079515 - 16 July 2026

Abstract Objectives: Lung adenocarcinoma (LUAD) has a poor prognosis, and effective metabolic biomarkers are still few. Glutamine metabolism is one of the central features of tumor metabolic reprogramming, but the cellular heterogeneity and clinical significance of glutamine metabolism in the LUAD tumor microenvironment (TME) remain unknown. The goal of this paper was to define glutamine metabolism on a single-cell basis and determine major regulators that have predictive value. Methods: A single-cell RNA sequencing dataset (GSE149655) was combined with The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) and Gene Expression Omnibus (GEO) datasets in order to evaluate the… More >

Zhihao Wei^1,#, Jijie Cai^1,#, Sifen Wang^2,#, Yachen Li³, Libo Luo¹, Jun Chen¹, Fuyu Li¹, Hongyu Nie¹, Ke Gong^4,*, Manbo Cai^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079281 - 16 July 2026

Abstract Breast cancer (BC) remains a leading cause of cancer-related mortality worldwide, and accumulating evidence suggests that tumor-associated microbiota may contribute to disease heterogeneity beyond host genetic and immune determinants. Advances in sequencing and multi-omics technologies have uncovered a reproducible intratumoral microbiome in BC, with distinct compositional patterns associated with molecular subtypes, clinicopathological features, and clinical outcomes. Alterations in specific microbial taxa have also been linked to tumor immune status, metastatic potential, and therapeutic sensitivity, underscoring their potential value in disease stratification and prognostic assessment. Although breast tissue represents a low-biomass environment, multiple studies employing stringent… More >